Scleromyxedema is a rare paraneoplastic fibromucinous connective tissue disorder characterized by papular mucinosis, monoclonal gammopathy and extracutaneous involvements. 1 It tends to have a chronic and progressive course, with a high mortality rate from extracutaneous involvements. 2 Response to alkylator-based chemotherapy or other therapies tends to be short. 2, 3 Chronic oral lowdose melphalan is the most commonly used chemotherapy, but rarely results in durable remissions, and is associated with a 30% TRM rate. 2 A few reports suggest significant potential benefit of high-dose chemotherapy (HDCT) and auto-SCT for scleromyxedema patients. [4] [5] [6] [7] [8] We report a case of life-threatening scleromyxedema, refractory to prior oral melphalan, but successfully treated with HD melphalan, BU and auto-SCT, with complete clinical remission at 5 years following treatment.
A 51-year-old male presented in March of 2002 with progressive and treatment-refractory scleromyxedema for consideration of auto-SCT. He had a history of pruritic 'hardened shiny lumps' over diffusely thickened skin since 1998. Medical conditions included diabetes, recurrent deep venous thrombosis, hypertension and gout. He had no thyroid disorder. He had a monoclonal IgG-l paraproteinemia and skin biopsy revealed dermal deposition of acidic mucin, diffuse fibroblastic proliferation and focal chronic inflammation. He had received therapies with prednisone, colchicine, penicillamine, methotrexate, melphalan with prednisone and pulse methylprednisolone. His melphalan treatment was started at 10 mg and escalated to 24 mg with prednisone at 100 mg, daily for 4 days per month for 9 months.
He did not experience clinically meaningful benefit from his treatments. Repeat skin biopsies showed advancing dermal changes with increasing cellularity and mucin deposition. Serum protein electrophoresis revealed a persistent IgG-l-band and the quantitative immunoglobulin analysis disclosed mild suppression of IgM. Some skin lesions reached 3 cm in size. He developed dysphagia, dyspnea, carpal tunnel syndrome, peripheral neuropathy, peripheral edema, muscle weakness, change in voice, erectile dysfunction and Raynaud's syndrome. His dysphagia was severe and required a liquid diet and periodic esophageal dilatations. By the spring of 2002, he was unable to selfcare, with a Karnofsky performance status of 40%.
On physical examination, he had shiny firm white papules, particularly over his extremities, and a leonine face with lumps in the glabella that had formed a cobblestone appearance (Figure 1a ). His face was erythematous and his trunk was hyperpigmented. He was unable to speak properly due to decreased oral aperture ( Figure 1b) . He had severe sclerodactyly and could not make a complete handgrip (Figure 1c) . He had diffusely thickened skin and pitting edema with decreased peripheral circulation in his lower extremities. Laboratory investigation revealed total serum protein level of 61 g/l (normal 63-80), albumin of 38 g/l (normal 40-56) and b-2-microglobulin of 3.11 mg/l. Serum protein electrophoresis revealed IgG-l at 2.4 g/l. Flow cytometry of his BM aspirate revealed a population of dim CD45/bright CD38 cells with l-light-chain restriction, comprising 0.5% of all nucleated cells. Cytogenetics analysis revealed normal male karyotype. Pulmonary function tests revealed mild reduction in diffusing capacity.
The patient consented to HDCT and auto-SCT. PBSCs were collected with two large volume apheresis procedures after mobilization with CY 2 g/m 2 , i.v., on day 1 followed by G-CSF (5 mg/kg) twice daily, s.c., from day 7-12. The HDCT conditioning regimen consisted of BU 3.2 mg/kg, i.v., daily on days À6 to À3 (total dose 12.8 mg/kg), melphalan 140 mg/m 2 , i.v., on day À2, rest day on day À1 and autologous stem cell infusion day 0 with G-CSF 480 mg, s.c., daily starting day þ 7. The infused CD34 þ cell dose was 3.37 Â 10 6 /kg. Hematological recovery postauto-SCT was prompt, with platelet count 420 Â 10 9 /l on day 6 and ANC 40.5 Â 10 9 /l on day 8. Toxicity included febrile neutropenia, severe stomatitis requiring parenteral narcotics, mild diarrhea, but no major organ toxicity or infection.
Clinical response was based on serial functional inquiry, quality of life assessment, clinical examination and photographs. The cutaneous papules, thickening and edema began to regress within days following auto-SCT and eventually resolved completely. He returned to full-time employment 5 weeks post auto-SCT. All symptoms from scleromyxedema resolved within 6 months (Figures 1d-f) . At 5-year follow-up, he was working full time with no symptoms of scleromyxedema. Hematological response was based on serum protein electrophoresis with immunofixation, BM biopsy and laboratory assessment. A very faint monoclonal IgG-l-band was detectable by immunofixation at 6 months post auto-SCT. This band remained detectable by immunofixation, but unmeasurable on multiple serum protein electrophoresis, with the last one performed in August 2007. Two IgG-k-bands appeared at 6 months post auto-SCT and disappeared by March 2006. This was interpreted as an oligoclonal restriction following auto-SCT. BM aspirate and biopsy revealed normal morphology, normal cell counts and disappearance of plasma cells with l-light chain restriction. His other laboratory investigations normalized and remained normal.
We report successful use of HD melphalan and BU as pre-auto-SCT conditioning regimen for scleromyxedema. This case describes complete clinical remission with the longest follow-up in the reported literature using auto-SCT for scleromyxedema. This patient did not receive single agent HD melphalan in view of his extensive prior melphalan therapy. We added BU based on its synergistic effect with melphalan and the successful use of this combination for multiple myeloma patients undergoing second HDCT at our institution. Several reports have shown auto-SCT to be effective often with dramatic clinical benefit for patients with scleromyxedema (Table 1) . Most protocols used HD melphalan as conditioning therapy. 
Letter to the Editor
In conclusion, we add support to the existing literature reporting consistent clinical benefit in using HDCT and auto-SCT for scleromyxedema. This treatment is still possible for patients who are heavily pretreated. The addition of BU to melphalan may have contributed to the success. Further study may explore this combination conditioning regimen for treating scleromyxedema. 
